Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Gastrointestinal 1

Conditions

Breast Neoplasms 19Glioma 5Neoplasms 4Neoplasm Metastasis 4Carcinoma, Non-Small-Cell Lung 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Ovarian Neoplasms 3Neuroblastoma 3Medulloblastoma 3Glioblastoma 3Colorectal Neoplasms 3Rhabdoid Tumor 2Lymphoma 2Lung Neoplasms 2Liposarcoma 2Diffuse Intrinsic Pontine Glioma 2Carcinoma, Ovarian Epithelial 2Brain Neoplasms 2Astrocytoma 2Stomach Neoplasms 1Sarcoma, Synovial 1Sarcoma 1Rhabdomyosarcoma 1Pyloric Stenosis, Hypertrophic 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pinealoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Oligodendroglioma 1

Interventions

pembrolizumab 28Cisplatin 24Oxaliplatin 22Irinotecan 22Fluorouracil 22Capecitabine 20Leucovorin 17Paclitaxel 16Cyclophosphamide 14Trastuzumab 12Nivolumab 11Carboplatin 11Gemcitabine 10Bevacizumab 10Docetaxel 9fludarabine 8aldesleukin 8S 1 (combination) 8Ramucirumab 7130-nm albumin-bound paclitaxel 7atezolizumab 6Albumin-Bound Paclitaxel 6Taxes 5Radiotherapy 5Magnetic Resonance Spectroscopy 5Biopsy 5veliparib 4tislelizumab 4spartalizumab 4dehydroftorafur 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Stomach Neoplasms × ribociclib × Clear all
NCT05252416 2025-11-28

(VELA) Study of BLU-222 in Advanced Solid Tumors

Blueprint Medicines Corporation

Phase 1 Terminated
50 enrolled
GastrointestinalGynecologicSarcoma

Adenocarcinoma Of Esophagus, Carcinosarcoma, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡